"Mnoho\u010Detn\u00FD myelom je druhou nej\u010Dast\u011Bj\u0161\u00ED a ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F st\u00E1le nevyl\u00E9\u010Ditelnou hematologickou malignitou. V\u00FDzkum biologick\u00E9 povahy choroby vede k identifikaci mechanizm\u016F, kter\u00E9 mohou b\u00FDt c\u00EDlem nov\u00FDch terapeutick\u00FDch postup\u016F. V sou\u010Dasnosti je to hlavn\u011B z\u00E1sah do interakc\u00ED mezi myelomov\u00FDmi bu\u0148kami a mikroprost\u0159ed\u00EDm kostn\u00ED d\u0159en\u011B a ovlivn\u011Bn\u00ED nitrobun\u011B\u010Dn\u00FDch metabolick\u00FDch proces\u016F v n\u00E1dorov\u00FDch bu\u0148k\u00E1ch. Jednou skupinou l\u00E1tek zasahuj\u00EDc\u00EDch do nitrobun\u011B\u010Dn\u00E9ho metabolizmu (princip ozna\u010Dovan\u00FD jako c\u00EDlen\u00E1 - targeted terapie) jsou inhibitory proteazomu a bortezomib (Velcade) je prvn\u00EDm z\u00E1stupcem t\u00E9to skupiny, kter\u00FD je vyu\u017E\u00EDv\u00E1n v klinick\u00E9 praxi."@cs . . "Gregora, E." . "Bortezomib (Velcade) in relapsed/refractory multiple myeloma-the first experience in the Czech Republic"@en . "Bortezomib (Velcade) in relapsed/refractory multiple myeloma-the first experience in the Czech Republic"@en . "H\u00E1jek, Roman" . "Inhibitor proteazomu - bortezomib (Velcade) - v l\u00E9\u010Db\u011B refraktern\u00EDho mnoho\u010Detn\u00E9ho myelomu Prvn\u00ED zku\u0161enosti v \u010Cesk\u00E9 republice" . "525012" . "Mnoho\u010Detn\u00FD myelom je druhou nej\u010Dast\u011Bj\u0161\u00ED a ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F st\u00E1le nevyl\u00E9\u010Ditelnou hematologickou malignitou. V\u00FDzkum biologick\u00E9 povahy choroby vede k identifikaci mechanizm\u016F, kter\u00E9 mohou b\u00FDt c\u00EDlem nov\u00FDch terapeutick\u00FDch postup\u016F. V sou\u010Dasnosti je to hlavn\u011B z\u00E1sah do interakc\u00ED mezi myelomov\u00FDmi bu\u0148kami a mikroprost\u0159ed\u00EDm kostn\u00ED d\u0159en\u011B a ovlivn\u011Bn\u00ED nitrobun\u011B\u010Dn\u00FDch metabolick\u00FDch proces\u016F v n\u00E1dorov\u00FDch bu\u0148k\u00E1ch. Jednou skupinou l\u00E1tek zasahuj\u00EDc\u00EDch do nitrobun\u011B\u010Dn\u00E9ho metabolizmu (princip ozna\u010Dovan\u00FD jako c\u00EDlen\u00E1 - targeted terapie) jsou inhibitory proteazomu a bortezomib (Velcade) je prvn\u00EDm z\u00E1stupcem t\u00E9to skupiny, kter\u00FD je vyu\u017E\u00EDv\u00E1n v klinick\u00E9 praxi." . . "14110" . . . "Maisnar, Vladim\u00EDr" . "4"^^ . . . "Adam, Zden\u011Bk" . . "\u0160traub, J." . "3"^^ . . "[77E39F59BFE6]" . "Klener, P." . "\u010Casopis l\u00E9ka\u0159\u016F \u010Desk\u00FDch" . "S, V" . "bortezomib; velcade; multiple myeloma"@en . "RIV/00216224:14110/05:00035894!RIV10-MSM-14110___" . "144" . "0008-7335" . "Inhibitor proteazomu - bortezomib (Velcade) - v l\u00E9\u010Db\u011B refraktern\u00EDho mnoho\u010Detn\u00E9ho myelomu Prvn\u00ED zku\u0161enosti v \u010Cesk\u00E9 republice" . "Multiple myeloma is the second most prevalent and mostly fatal hematologic cancer. Further advances have been made in understanding the mechanisms involved in the myeloma pathogenesis and elucidation of critical signalling pathways as therapeutical targets. Proteasome inhibitors are the example of this new approach and bortezomib is the first agent in this class to enter clinical trials."@en . . "10"^^ . "\u0160\u010Dudla, Vlastimil" . "Schutzov\u00E1, M." . . . "Vyt\u0159asov\u00E1, M." . . . "Inhibitor proteazomu - bortezomib (Velcade) - v l\u00E9\u010Db\u011B refraktern\u00EDho mnoho\u010Detn\u00E9ho myelomu Prvn\u00ED zku\u0161enosti v \u010Cesk\u00E9 republice"@cs . "RIV/00216224:14110/05:00035894" . "CZ - \u010Cesk\u00E1 republika" . "9" . . . "Inhibitor proteazomu - bortezomib (Velcade) - v l\u00E9\u010Db\u011B refraktern\u00EDho mnoho\u010Detn\u00E9ho myelomu Prvn\u00ED zku\u0161enosti v \u010Cesk\u00E9 republice"@cs . . . "\u0160pi\u010Dka, Ivan" . .